Literature DB >> 12123804

A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains.

Huang Chun Tseng1, Ying Zhou, Yong Shen, Li Huei Tsai.   

Abstract

P25, a calpain cleavage product of the cyclin-dependent kinase 5 (Cdk5) activator p35, causes prolonged activation of Cdk5. Although p25 has been shown to accumulate in brains of patients with Alzheimer's disease (AD), it is not known whether p25 accumulation in AD is brain region-specific. We analyzed the amounts of p25 and p35 in human autopsy samples from multiple brain regions including frontal cortex, inferior parietal cortex and hippocampus using immunoblotting assays. Our results show that the p25-p35 indices are higher in AD than in the control groups in all three brain regions. The most significant difference in p25-p35 indices between AD and control groups is in the frontal cortex. No significant difference in calpain activity between AD and control groups is observed, indicating that postmortem calpain activation cannot account for the elevation of p25/p35 ratios in AD brains. Our results support the notion that p25 accumulation deregulates Cdk5 activity in AD brains, and the deregulated Cdk5 activity may contribute to the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123804     DOI: 10.1016/s0014-5793(02)02934-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  50 in total

Review 1.  Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status.

Authors:  Naoya Yamashita; Yoshio Goshima
Journal:  Mol Neurobiol       Date:  2012-02-18       Impact factor: 5.590

2.  A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Authors:  Ya-Li Zheng; Niranjana D Amin; Ya-Fang Hu; Parvathi Rudrabhatla; Varsha Shukla; Jyotshnabala Kanungo; Sashi Kesavapany; Philip Grant; Wayne Albers; Harish C Pant
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

3.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

4.  Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.

Authors:  Yi Wen; W Haung Yu; Bryan Maloney; Jason Bailey; Junrong Ma; Isabelle Marié; Thomas Maurin; Lili Wang; Helen Figueroa; Mathieu Herman; Pavan Krishnamurthy; Li Liu; Emmanuel Planel; Lit-Fui Lau; Debomoy K Lahiri; Karen Duff
Journal:  Neuron       Date:  2008-03-13       Impact factor: 17.173

5.  Gel-based protease proteomics for identifying the novel calpain substrates in dopaminergic neuronal cell.

Authors:  Chiho Kim; Nuri Yun; Young Mook Lee; Jae Y Jeong; Jeong Y Baek; Hwa Young Song; Chung Ju; Moussa B H Youdim; Byung K Jin; Won-Ki Kim; Young J Oh
Journal:  J Biol Chem       Date:  2013-11-14       Impact factor: 5.157

6.  Hippocampal glycogen synthase kinase 3β is critical for the antidepressant effect of cyclin-dependent kinase 5 inhibitor in rats.

Authors:  Gang Li; Ting Liu; Xiangqian Kong; Lei Wang; Xing Jin
Journal:  J Mol Neurosci       Date:  2014-02-22       Impact factor: 3.444

7.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

8.  PHF-like tau phosphorylation in mammalian hibernation is not associated with p25-formation.

Authors:  Jens Thorsten Stieler; Torsten Bullmann; Franziska Kohl; Brian M Barnes; Thomas Arendt
Journal:  J Neural Transm (Vienna)       Date:  2009-01-28       Impact factor: 3.575

9.  Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening.

Authors:  Anne Jämsä; Karin Agerman; Ann-Cathrin Radesäter; Jan Ottervald; Jonas Malmström; Gösta Hiller; Gang Liu; Mervi Vasänge
Journal:  J Biomed Sci       Date:  2009-06-17       Impact factor: 8.410

10.  COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo.

Authors:  Ying Tong; Ying Xu; Kimberly Scearce-Levie; Louis J Ptácek; Ying-Hui Fu
Journal:  Neurogenetics       Date:  2009-06-23       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.